Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 23 jul 2014 - 07:30

Statutaire naam Galapagos NV

Titel MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

Bericht Martinsreid/Munich, Germany and Mechelen, Belgium; 23 July 2014 - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext: GLPG; OTC: GLPYY) announced today that the first program from their strategic alliance has advanced into preclinical development. MOR106 was realized based on a novel Galapagos target and MorphoSys' next-generation antibody library Ylanthia and will now be jointly developed in inflammatory diseases.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201407230000000003_Galapagos en MorphoSys brengen antilichaam tegen ontstekingsziekten in preklinische ontwikkeling.pdf (opens in a new window)

201407230000000003_MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development.pdf (opens in a new window)

Datum laatste update: 26 april 2025